Skip to content

Kansas City Vascular Institute successfully implanted a first-of-its-kind dissolvable stent

Kansas City Vascular Institute successfully implanted a first-of-its-kind dissolvable stent

Kansas City Vascular Institute has successfully implanted a first-of-its-kind dissolvable stent, a new FDA-approved treatment option for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK), Abbott’s Esprit™ BTK System.

• Abbott’s Esprit™ BTK System is a first-of-its kind dissolvable stent designed to keep arteries

open and deliver a drug to support vessel healing prior to dissolving over time.

• Abbott’s Esprit™ BTK System is implanted during a minimally invasive catheter-based

procedure via a small incision in the leg. Once the blockage is open, the Esprit™ BTK System

keeps the arteries open and delivers a drug called Everolimus, to support vessel healing until

it is strong enough to remain open on its own.

• Abbott’s Esprit™ BTK System addresses an unmet need for people living with chronic limb threatening ischemia (CLTI) below-the-knee (BTK), a serious form of peripheral artery

disease (PAD). CLTI BTK occurs when arteries become clogged with plaque, preventing

blood flow and oxygen from reaching the lower leg and foot.

• Until now, there were limited treatment options approved for blocked arteries below the knee

in the U.S.

• Peripheral artery disease (PAD) is highly prevalent, yet many people have never heard of it.

Over 20 million people in the U.S. are living with this painful disease and only 10% of these

people have been diagnosed.1,2

Abbott’s Esprit™ BTK System better enables Kansas City Vascular to achieve our mission of saving and improving the lives of our patients by providing the most advanced minimally invasive techniques available in an office setting. 

Powered By GrowthZone